{
  "source": "PA-Notification-Livtencity.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1378-4\nProgram Prior Authorization/Notification\nMedication Livtencity (maribavir)\nP&T Approval Date 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nLivtencity is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated in adults and\npediatric patients (12 years of age and older and weighing at least 35 kg) for the treatment of\npost-transplant CMV infection/disease that is refractory to treatment (with or without\ngenotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. Livtencity may\nantagonize the antiviral activity of ganciclovir and valganciclovir and coadministration is not\nrecommended.\n2. Coverage Criteriaa:\nA. Authorization\n1. Livtencity will be approved based on the following criterion:\na. Diagnosis of post-transplant cytomegalovirus (CMV) infection or CMV disease\n-AND-\nb. CMV infection or disease is refractory to treatment (with or without genotypic\nresistance) to one of the following:\n(1) Ganciclovir\n(2) Valganciclovir\n(3) Cidofovir\n(4) Foscarnet\n-AND-\nc. Patient is not receiving Livtencity in combination with ganciclovir or\nvalganciclovir\nAuthorization will be issued for 2 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n4. References:\n1. Livtencity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.;\nMarch 2024.\nProgram Prior Authorization/Notification – Livtencity (maribavir)\nChange Control\n2/2022 New pr",
    "erences:\n1. Livtencity [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.;\nMarch 2024.\nProgram Prior Authorization/Notification – Livtencity (maribavir)\nChange Control\n2/2022 New program.\n2/2023 Annual review. Added state mandate and updated reference.\n2/2024 Annual review. Updated background and reference.\n2/2025 Annual review. Updated background and reference.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}